Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data.
Lisa J McGarryZahra BhaiwalaAndrea LopezConor ChandlerChristopher G PelligraJaime L RubinTheodore G LiouPublished in: PloS one (2023)
Modeled 5-year survival projections for people with CF initiating ivacaftor vs. standard care align closely with real-world registry data. Findings support the validity of modeling CF to predict long-term survival and estimate clinical and economic outcomes of CFTRm.
Keyphrases
- cystic fibrosis
- pseudomonas aeruginosa
- lung function
- electronic health record
- big data
- healthcare
- free survival
- palliative care
- transcription factor
- quality improvement
- data analysis
- machine learning
- type diabetes
- chronic pain
- artificial intelligence
- chronic obstructive pulmonary disease
- skeletal muscle
- low cost
- air pollution
- health insurance